Cyclic AMP-specific phosphodiesterase inhibitors

A compound having the formula:

• wherein Y is O or NR4;
• R1 is selected from the group consisting of lower alkyl, bridged alkyl, aralkyl, cycloalkyl, a 5- or 6-membered saturated heterocycle, C1-3alkylenecycloalkyl, aryl- or heteroaryl-substituted propargyl, aryl- or heteroaryl-substlituted allyl, and halocycloalkyl;
• R2 is hydrogen, methyl, or halo-substituted methyl;
• R3 is selected from the group consisting of C(═O)OR7, C(═O)R7, C(═NH)NR8R9, C(═O)NR8R9, lower alkyl, bridged alkyl, cycloalkyl, haloalkyl, halocycloalkyl, C1-3alkylenecycloalkyl, a 5- or 6-membered saturated heterocycle, aryl, heteroaryl, heteroarlySO2, aralkyl, alkaryl, heteroaralkyl, heteroalkaryl, C1-3alkyleneC(═O)OR7, C(═O)C1-3alkyleneC(═O)OR7, C1-3alkyleneheteroaryl, C(═O)C(═O)OR7, C(═O)C1-3alkyleneC(═O)OR7, C(═O)C1-3alkyleneNH(C═O)OR7, C(═O)C1-3alkyleneNH2, and NHC(═O)OR7;
• R4 is hydrogen, lower alkyl, haloalkyl, cycloalkyl, aryl, or hereroaryl;
• R7 is selected from the group consisting of cycloalkyl, branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and aryl, and R7 can be optionally substituted with one or more of OR8, NR8R9, or SR8;
• R8 and R9, same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, heteroalkaryl, and aralkyl, or R8 and R9 together form a 4-membered to 7-membered ring;
• R10 is hydrogen, alkyl, haloalkyl, cyclcalkyl, aryl, C(═O)alkyl, C(═O)cycloalkyl, C(═O)aryl, C(═O)Oalkyl, C(═O)Ocycloalkyl, C(═O)aryl, CH2OH, CH2Oalkyl, CHO, CN, NO2, or SO2R11;
• and
• R11 is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR8R9.